Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
‘Impressive’ results with neoadjuvant T-VEC in advanced melanoma
Key clinical point: In patients with advanced resectable melanoma, neoadjuvant intralesional talimogene laherparepvec plus surgery remained superior to immediate surgery at 3 years of follow-up.
Major finding: The 3-year rate of recurrence-free survival was 46.5% with talimogene laherparepvec plus surgery and 31.0% with immediate surgery (hazard ratio, 0.67; P = .043).
Study details: A phase 2 trial of talimogene laherparepvec followed by surgery versus immediate surgery in 150 patients with resectable stage IIIB–IV M1a melanoma.
Disclosures: The trial was funded by Amgen. Dr. Dummer disclosed relationships with Amgen, Novartis, Merck Sharp & Dohme, Bristol-Myers Squibb, Roche, Takeda, Pierre Fabre, Sun Pharma, Sanofi, and CatalYm.
Dummer R et al. SITC 2020,Abstract 432.